Skip to main content
Formycon AG logo

Formycon AG — Investor Relations & Filings

Ticker · FYB ISIN · DE000A1EWVY8 LEI · 39120005TZ76GQOY8Z19 F Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2023-02-01 Capital/Financing Update
Country DE Germany
Listing F FYB

About Formycon AG

https://www.formycon.com/en/

Formycon AG is an independent, globally operating biopharmaceutical company specializing in the development of high-quality biosimilars. As a pure-play biosimilar developer, the company focuses on creating follow-on products for complex biopharmaceutical medicines after their patent protection has expired. The core mission is to enhance patient access to safe, effective, and affordable biologic therapies. Formycon's development activities are concentrated in therapeutic areas with high medical need, including ophthalmology and immunology. The company manages the entire development process, from analytics and process development to clinical trials and regulatory approval submissions for its biosimilar candidates.

Recent filings

Filing Released Lang Actions
Formycon AG upsizes capital increase from authorized capital following strong demand
Capital/Financing Update Classification · 99% confidence The document is an 'Ad-hoc' announcement dated February 1, 2023, explicitly titled 'Formycon AG upsizes capital increase from authorized capital following strong demand'. It details the decision to increase share capital by issuing new shares to raise funds for development and balance sheet strengthening. This directly relates to fundraising, financing activities, and capital structure changes. Based on the provided definitions, this aligns perfectly with the 'Capital/Financing Update' category, coded as CAP.
2023-02-01 English
Formycon AG announces global license agreement with Fresenius Kabi for FYB202, a biosimilar candidate to Stelara1 (ustekinumab)
Major Shareholding Notification Classification · 99% confidence The document is an 'Ad-hoc' announcement dated February 1, 2023, disclosing inside information pursuant to Article 17 of Regulation (EU) No 596/2014 (MAR). The core content is the announcement of a 'global license agreement' between Formycon AG and Fresenius Kabi regarding a biosimilar candidate (FYB202). This type of announcement, detailing a significant business transaction (alliance/licensing) that is material to the company's operations and financial standing, is typically classified as a general regulatory filing or an announcement related to corporate activity. Since there is no specific category for 'License Agreement' or 'Alliance,' and it is a mandatory disclosure under EU regulation (MAR), it fits best under the general regulatory announcement category, RNS, or potentially CAP if it were purely about financing, but this is a commercial deal. Given the context of mandatory disclosure of material non-public information (inside information) under MAR, RNS (Regulatory Filings) is the most appropriate general classification for such an ad-hoc announcement that isn't a standard financial report (10-K, IR, ER) or a specific corporate action like a dividend or share issue.
2023-02-01 English
Formycon announces binding Term Sheet between Klinge Biopharma and Coherus BioSciences for the exclusive commercialization of FYB203, a biosimilar candidate to Eylea1, in the United States
M&A Activity Classification · 99% confidence The document is an 'Ad-hoc' announcement dated January 9, 2023, disclosing an 'inside information acc. to Article 17 MAR'. It details a binding Term Sheet between Klinge Biopharma and Coherus BioSciences regarding the commercialization rights for a biosimilar candidate (FYB203). This type of announcement, which conveys material, non-public information about a significant business agreement (alliance/licensing deal) outside of routine financial reporting periods (like 10-K or IR), typically falls under general regulatory disclosure mechanisms. Since it is not a specific financial report (10-K, IR, ER), a management change (MANG), a dividend notice (DIV), or a specific shareholder vote result (DVA), it best fits the general 'Regulatory Filings' category (RNS) as a mandatory disclosure under MAR (Market Abuse Regulation). It is not a Report Publication Announcement (RPA) because it is the substance of the news itself, not just an announcement that a report is available.
2023-01-09 English
Formycon Reports its Nine-month Figures for 2022
Earnings Release Classification · 100% confidence The document is titled "Formycon Reports its Nine-month Figures for 2022" and contains key financial metrics (turnover, EBITDA, EBIT, net result) for the first nine months of the fiscal year, along with a forecast for the full year. This content structure is characteristic of a comprehensive financial report covering a period shorter than a full year, specifically a nine-month report. This aligns directly with the definition of an Interim / Quarterly Report (IR). Although it is presented as a press release via EQS News, the core content is the detailed financial results for the interim period, not just a brief announcement of results (ER) or an announcement that a report is attached (RPA). 9M 2022
2022-11-25 English
Broad-acting antiviral SARS-CoV-2 drug FYB207 shows longer half-life and improved efficacy through optimized molecular design in preclinical studies
Earnings Release Classification · 99% confidence The document is a press release dated November 3, 2022, announcing preclinical study results for a drug candidate (FYB207) against SARS-CoV-2. It details scientific findings (half-life, efficacy, molecular design) and mentions future plans (GMP production, clinical trial entry in 2023). It is not a formal regulatory filing like a 10-K, nor is it a transcript (CT), a dividend notice (DIV), or a management discussion (MDA). Since it is an announcement of scientific/development progress, it fits best under the general category for corporate news that isn't strictly financial results or governance, which points towards Regulatory Filings (RNS) as the most appropriate general category for non-standard corporate updates, or potentially Investor Presentation (IP) if it were structured as a presentation, but this is a press release. Given the options, and that it is a news announcement about R&D progress, RNS (Regulatory Filings/General Announcement) is the best fit, as it is not an Earnings Release (ER) or an Interim Report (IR). FY 2022
2022-11-03 English
Formycon reports final figures for the first half of 2022
Earnings Release Classification · 100% confidence The document is titled "Formycon reports final figures for the first half of 2022" and explicitly mentions publishing its "half-year report 2022". It contains detailed financial figures (turnover, EBITDA, EBIT, balance sheet extracts) for the first six months (H1/2022) under IFRS. This content aligns perfectly with the definition of a comprehensive financial report for a period shorter than a year. Therefore, the classification is Interim / Quarterly Report (IR). Although it mentions the full report is available via a link, the provided text contains the core content of the report itself, not just an announcement of its publication (which would be RPA/RNS). H1 2022
2022-10-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.